kyron.bio has developed a platform that fully controls N-glycosylation to precisely define glycans on therapeutics, addressing immune recognition and variable efficacy in antibody drugs. The platform combines novel engineered CHO cell lines and a proprietary glycan-engineering toolbox to enable comprehensive control of glycosylation during production. It achieves over 97% consistency in glycan structures and is offered as a scalable, plug-and-play solution compatible with standard biopharma manufacturing techniques. This level of control is intended to prevent unwanted immune attack, improve therapeutic stability and targeting, and unlock new antibody engineering opportunities. The company announced a €5.5M funding round to accelerate development of its glycan-engineering platform, expand the team and fund preclinical studies. The funding also coincides with the launch of the company’s EIC Transition project backed by the European Innovation Council.

Total raised

$6M

Funding rounds

1

Latest round

Seed

Latest activity

May 2025